AMER SOC HEMATOLOGY

• 

  Publisher Of

  • Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.  Blood.  128:3083-3100. 2016
  • GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo.  Blood.  127:2723-2731. 2016
  • Cerebral Ischemia in Adults with Sickle Cell Disease after First Stroke.  Blood.  124. 2014
  • Health-Related Quality of Life in Children with Sickle Cell Disease: Impact of Blood Transfusion Therapy.  Blood.  124. 2014
  • Impact of Comorbidities on Length of Stay and Mortality in Hospitalized Patients with Cancer and Febrile Neutropenia.  Blood.  124. 2014
  • MEK Inhibitors, Novel Anti-Adhesive Molecules, Reverse Sickle Red Blood Cell Adhesion and Vaso-Occlusion in Vivo.  Blood.  124. 2014
  • Patent Foramen Ovale in Adult Patients with Sickle Cell Disease and Stroke.  Blood.  124. 2014
  • Prognostic Disclosure in Acute Myeloid Leukemia (AML): A Qualitative Study of Patient Preferences and Physician Practices.  Blood.  124. 2014
  • The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia.  Blood.  124. 2014
  • The Use of Chronic Transfusions in Sickle Cell Disease for Non-Stroke Related Indications.  Blood.  124. 2014
  • Venous Thromboembolism (VTE) Surveillance: Incidence, Characteristics, and Initial Treatment of VTE Patients.  Blood.  124. 2014
  • Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.  Blood.  124:1915-1925. 2014
  • A Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme (R) Infusions Every 4 Weeks Versus Every 2 Weeks in the Maintenance Therapy of Patients with Type 1 Gaucher Disease.  Blood.  112:460-460. 2008
  • A Phase I/II Study with CP-4055 in Patients with Haematologic Malignancies..  Blood.  112:350-350. 2008
  • Adherence with Hydroxyurea in Children with Sickle Cell Disease.  Blood.  112:69-69. 2008
  • Antecedent Transfusion and Primary Hemorrhagic Stroke in Adults with Sickle Cell Disease..  Blood.  112:512-512. 2008
  • Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity.  Blood.  112:140-140. 2008
  • Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.  Blood.  112:1142-1142. 2008
  • Complications of Hysterectomy in Women with Von Willebrand Disease.  Blood.  112:1166-1166. 2008
  • Development of mPF4/Heparin Antibodies in a Murine Platelet Activation Model.  Blood.  112:106-107. 2008
  • Differential Impact of Inhibitory and Activating Killer Ig-Like Receptors and HLA Ligand on Outcomes of Transplantation for Myeloid and Lymphoid Malignancies.  Blood.  112:1118-1118. 2008
  • Does Living Closer to a Medical Care Center Matter in Sickle Cell Disease?.  Blood.  112:323-324. 2008
  • Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.  Blood.  112:760-760. 2008
  • Encoraging Results after Alternative Donor Transplantation for Myelodysplastic Syndrome.  Blood.  112:685-686. 2008
  • Erythrocyte Adhesion and Phosphatidylserine Exposure in HbSC Disease: Baseline Data from the CHAMPS Study..  Blood.  112:861-861. 2008
  • Functional and Biochemical Changes in Stored Human Red Blood Cells.  Blood.  112:1355-1355. 2008
  • Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia.  Blood.  112:785-786. 2008
  • Genomic Approaches to Identifying Risk for Pulmonary Artery Hypertension among Individuals with Sickle Cell Disease..  Blood.  112:514-514. 2008
  • Identification of Therapeutic Targets for Chronic Lymphocytic Leukemia in the Relapsed and Refractory Setting.  Blood.  112:720-720. 2008
  • Increased Hepcidin Expression in Mice Affected by beta-Thalassemia Reduces Iron Overload with No Effect on Anemia.  Blood.  112:53-53. 2008
  • Isolation and Expansion of Oligodendrocytes from Thawed, Cryopreserved Human Umblilical Cord Blood.  Blood.  112:1193-1193. 2008
  • MicroRNAs Distinguish Burkitt Lymphoma from the Molecular Subsets of Diffuse Large B Cell Lymphoma.  Blood.  112:1151-1151. 2008
  • MicroRNAs Regulate Mature B Cell Differentiation.  Blood.  112:262-262. 2008
  • Monocytes Are a Particularly Favorable Target for Surface Platelet Factor 4 (PF4) Antigenic Complex Formation in Heparin-Induced Thrombocytopenia: New Insights into the Thrombotic Risk in HIT.  Blood.  112:107-107. 2008
  • Obstetric and Gynecological History in Sickle Cell Disease Females.  Blood.  112:867-868. 2008
  • Plasmacytoid CD123+Dendritic Cell Recovery Is An Independent Predictor of Survival after Unrelated Cord Blood Transplant (UCBT).  Blood.  112:777-777. 2008
  • Prolonged Survival despite High Disease Burden in Elderly (>= 55) Patients with Hb SS or Hb S beta 0 Thalassemia.  Blood.  112:264-264. 2008
  • Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation.  Blood.  112:133-134. 2008
  • Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML.  Blood.  112:1019-1020. 2008
  • Risk factors for primary hemorrhagic stroke in adults with sickle cell disease.  Blood.  110:19B-20B. 2007
  • Bleeding.Events and other complications during pregnancy and childbirth in women with Von Willebrand disease..  Blood.  108:302A-302A. 2006
  • Blocking adhesion of sickle erythrocytes to endothelial alpha V beta 3 using RNA aptamer..  Blood.  108:206A-207A. 2006
  • Genetic polymorphisms associated with priapism in sickle cell disease..  Blood.  108:236A-237A. 2006
  • Role of A91V mutation in perforin gene in hemophagocytic lymphohistiocytosis.  Blood.  104:1910-1910. 2004
  • Absolute lymphoid and myeloid dendritic cell counts in umbilical cord blood, bone marrow, and peripheral blood..  Blood.  98:321B-321B. 2001
  • Alemtuzumab (Campath) in relapsed or refractory CLL or PLL..  Blood.  98:290B-291B. 2001
  • Binding and uptake of PF4/heparin/antibody complexes in multiple cell types..  Blood.  98:35A-35A. 2001
  • Cord blood donor pre-screening: Impact of exclusion criteria on minority recruitment..  Blood.  98:104B-104B. 2001
  • Correction of Hurler Syndrome with unrelated umbilical cord blood transplantation..  Blood.  98:667A-667A. 2001
  • Cytokine modulation of inducible nitric oxide synthase (NOS2) mRNA levels and apoptosis in B-cell chronic lymphocytic leukemia (B-CLL): A quantitative analysis..  Blood.  98:362A-362A. 2001
  • Dose dense, high intensity therapy for mantle cell lymphoma..  Blood.  98:681A-682A. 2001
  • Durable engraftment of mismatched unrelated cord blood following a non-myeloablative preparative regimen for adults..  Blood.  98:185A-185A. 2001
  • Enrichment of donor erythroid cells after non-myeloablative bone marrow transplantation (BMT) for sickle cell anemia (SCA)..  Blood.  98:490A-490A. 2001
  • Flow cytometric analysis in two large cohorts of patients with PNH..  Blood.  98:221A-221A. 2001
  • Functional T cell immunity before myeloid engraftment by donor post-thymic T cells in pediatric unrelated cord blood transplant recipients..  Blood.  98:379A-379A. 2001
  • High-dose immunosuppressive therapy (HDIT) for severe systemic sclerosis (SSc)..  Blood.  98:395B-395B. 2001
  • Impaired anticoagulant response to thrombin improves after regression of atherosclerosis in monkeys..  Blood.  98:257A-257A. 2001
  • Increased microvessel density in non-Hodgkin's lymphoma (NHL) is localized to the site of disease changes in accordance with disease response..  Blood.  98:236B-236B. 2001
  • J82 cell inositol polyphosphatide signaling via factor Xa and factor VIIa: The possible role of protease-activated receptor 2 (PAR-2) activation..  Blood.  98:53B-53B. 2001
  • Lack of standardization of methodology for enumeration of CD34 in banked umbilical cord blood..  Blood.  98:333B-333B. 2001
  • Low dose, weekly, paclitaxel as salvage therapy for non-Hodgkins lymphoma (NHL)..  Blood.  98:246B-246B. 2001
  • MRD allo transplantation using a large volume leukopheresis product mobilized with G-CSF and Decadron, pharmacokinetics directed modest dose intravenous busulfan plus fludarabine conditioning, and long MTX/CSA results in sustained engraftment, low 30 day mortality, and low incidence of severe GVHD..  Blood.  98:200A-200A. 2001
  • Molecular evidence of engraftment in bone marrow after nonmyeloablative allogeneic stem cell transplant (NMASCT) is an unreliable indicator of residual/recurrent disease in the marrow..  Blood.  98:185A-185A. 2001
  • Molecular interaction of the Fanconi Anemia (FA) and Ataxia Telangiectasia (AT) pathways..  Blood.  98:782A-782A. 2001
  • Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population..  Blood.  98:853A-853A. 2001
  • Non-myeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells..  Blood.  98:420A-421A. 2001
  • Non-myeloablative transplantation using CAMPATH 1H for T depletion of mismatched, related donor peripheral blood stem cells..  Blood.  98:669A-669A. 2001
  • Phase I trial of prolonged infusion gemcitabine with fludarabine for relapsed/refractory acute leukemia..  Blood.  98:220B-221B. 2001
  • Prolonged infusion gemcitabine in combination with CPT-11 for relapsed or refractory hematologic malignancies..  Blood.  98:209B-209B. 2001
  • Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma (NHL)..  Blood.  98:247B-247B. 2001
  • Reconstitution of T cell and dendritic cell immunity 50 days post unrelated cord blood transplant predicts the incidence of opportunistic infections and acute GVHD in children..  Blood.  98:204A-204A. 2001
  • Red cell signaling pathways cause increased sickle cell adhesion to non-activated endothelial cells..  Blood.  98:484A-484A. 2001
  • Regulation of T and NK cell mediated cytotoxicity by the CD7 ligand, k12..  Blood.  98:23A-23A. 2001
  • Sickle red cell B-CAM/LU mediates adhesion to multiple sites of laminin under different conditions..  Blood.  98:484A-485A. 2001
  • The clinical course of PNH in the USA and in Japan..  Blood.  98:220A-220A. 2001
  • Treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT)..  Blood.  98:687A-687A. 2001
  • alpha-adducin connects actin filament barbed ends to the platelet membrane skeleton..  Blood.  98:787A-787A. 2001
  • Assay method, cord blood bank, nucleated cell count, and neonatal factors influence the CD34+cell count in cord blood: The COBLT experience..  Blood.  96:302B-302B. 2000
  • Banked umbilical cord blood is an excellent source of donor hematopoietic stem cells for infants with malignant and non-malignant conditions lacking a related donor..  Blood.  96:587A-+. 2000
  • Binding and activation of monocytes by PF4/heparin specific antibodies..  Blood.  96:269A-269A. 2000
  • Characterization of HLA polymorphism in an ethnically diverse cord blood bank..  Blood.  96:301B-301B. 2000
  • Cytokine regulation of inducible nitric oxide synthase (NOS2) and NOS2 inhibitor-induced apoptosis and death in chronic lymphocytic leukemia cells..  Blood.  96:159A-159A. 2000
  • Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases..  Blood.  96:406A-406A. 2000
  • Hematopoietic engraftment and survival after unrelated donor umbilical cord blood (UCB) transplantation in adult recipients..  Blood.  96:587A-+. 2000
  • Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model demonstrates the requirement for human platelet factor 4 and platelet activation through Fc gamma RIIA..  Blood.  96:221A-221A. 2000
  • High dose chemotherapy followed by transplantation of unrelated, banked, umbilical cord blood provides curative therapy for young pediatric patients with familial erythrophagocytic lymphohistiocytosis (FEL)..  Blood.  96:362B-362B. 2000
  • High-dose immunosuppressive therapy (HDIT) and autologous stem cell transplant for severe systemic sclerosis (SSc)..  Blood.  96:844A-844A. 2000
  • Human erythrocyte and endothelial cells contain tissue transglutaminase that can regulates inflammation and platelet function by binding and releasing nitric oxide..  Blood.  96:38A-38A. 2000
  • In vivo behavior of factor IX and certain GLA domain mutants evaluated in coagulation factor M-deficient mice..  Blood.  96:35A-35A. 2000
  • Inhibition of tyrosine kinase activity by SUGEN 5416 inhibits fibrin dependent angiogenesis..  Blood.  96:57B-57B. 2000
  • Inverse relationship of plasma prostaglandin-E-2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria..  Blood.  96:31B-31B. 2000
  • Limitations of using CD23 expression by flow cytometry to differentiate mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma..  Blood.  96:330A-330A. 2000
  • Low incidence of Epstein-Barr virus-associated post-transplant lymphoproliferative disorders (EBV-PTLD) in 263 unrelated donor umbilical cord blood transplant recipients..  Blood.  96:206A-206A. 2000
  • Nitric oxide as a nonprotein regulator of hematopoietic cell proliferation and differentiation-relationship to malarial anemia..  Blood.  96:14B-14B. 2000
  • Outcomes of unrelated umbilical cord blood transplantation in 158 pediatric patients consecutively transplanted at a single institution using cord blood units from a single bank..  Blood.  96:206A-206A. 2000
  • Overexpression of anti-apoptosis genes in association with resistance to apoptosis observed in bone marrow failure syndromes..  Blood.  96:526A-526A. 2000
  • Oxygen-dependent export of nitric oxide from red blood cells..  Blood.  96:596A-+. 2000
  • Pediatric ALK-positive lymphomas coexpress c-Myc..  Blood.  96:128A-128A. 2000
  • Phase I trial of continuously infused gemcitabine with CPT-11 for refractory hematologic malignancies..  Blood.  96:216B-216B. 2000
  • Phase I trial of continuously infused gemcitabine with mitoxantrone for high risk or relapsed acute leukemia..  Blood.  96:326A-326A. 2000
  • Phase I trial of escalting doses of 4-hydroxycyclophosphamide (4HC) purged autologous peripheral blood progenitor cells (PBPC) for leukemia..  Blood.  96:385A-385A. 2000
  • Predictive value of day+50 immune reconstitution on the incidence of opportunistic infections and acute GVHD following unrelated cord blood transplants in children..  Blood.  96:789A-789A. 2000
  • Preliminary characterization of the surface staining of placental derived adherent cells: A potential new source of stroma for umbilical cord blood (UCB) expansion..  Blood.  96:150B-150B. 2000
  • Relationship between transferrin saturation and iron stores in US African-American and Caucasian populations..  Blood.  96:226A-226A. 2000
  • Serum alpha-2 macroglobulin (alpha 2M) determines NAT binding capacity in patients with peripheral vascular disease (PVD)..  Blood.  96:273A-273A. 2000
  • Treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT)..  Blood.  96:842A-843A. 2000
  • Umbilical cord blood graft engineering using bone marrow stroma to enhance hematopoietic stem and progenitor cell content..  Blood.  96:774A-774A. 2000
  • Unrelated umbilical cord blood transplant for osteopetrosis..  Blood.  96:207A-207A. 2000
  • Use of serum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture..  Blood.  96:754A-754A. 2000
  • A Phase I study of 2-amino-9-B-D-arabinosyl-6-methoxy-9H-purine (506U78) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies..  Blood.  94:629A-629A. 1999
  • Absolute lymphoid and myeloid dendritic cell counts in umbilical cord blood grafts and in recipients of unrelated umbilical cord blood transplants..  Blood.  94:326B-326B. 1999
  • Acute lymphoblastic leukemia in infancy: Improved outcome with unrelated placental cord blood (PCB) transplants..  Blood.  94:712A-712A. 1999
  • Augmentation of umbilical cord blood (UCB) transplantation with ex vivo expaned cells, a phase I trial using the replicell system..  Blood.  94:571A-571A. 1999
  • Characterization of a monoclonal antibody to PF4/heparin (KKO) with functional and serologic properties of hit antibodies..  Blood.  94:21A-21A. 1999
  • Diffuse alveolar hemorrhage after hematopoietic stem cell transplantation for mucopolysaccharidosis type 6: Report of 3 cases..  Blood.  94:334A-335A. 1999
  • Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients..  Blood.  94:158A-158A. 1999
  • Human platelet adducin: A regulated actin filament barbed end-capping protein..  Blood.  94:216A-216A. 1999
  • Inducible nitric oxide synthase (NOS2) inhibitors induce high level CLL cell apoptosis and death..  Blood.  94:703A-703A. 1999
  • Laminin binding and B-CAM/LU expression by high and low density reticulocytes vs mature red cells in sickle cell disease..  Blood.  94:675A-675A. 1999
  • Manipulation of CD22 signal transduction for the treatment of lymphoma..  Blood.  94:93A-93A. 1999
  • Markers of angiogenesis, factor VIII and tenascin, correlate with disease activity in patients with Non-Hodgkin's Lymphoma..  Blood.  94:253B-253B. 1999
  • Stable mixed chimerism after bone marrow transplantation (BMT) for Sickle Cell Disease (SCD)..  Blood.  94:645A-645A. 1999
  • Stroma from adult bone marrow increases the productivity of ex vivo cord blood expansion cultures..  Blood.  94:164B-164B. 1999
  • The effect of cytokine combinations on the clinical scale ex-vivo expansion of umbilical cord blood..  Blood.  94:573A-573A. 1999
  • Transplantation of a patient with congenital neutropenia and invasive fungal disease with unrelated umbilical cord blood using paternal G-CSF mobilized, irradiated granulocyte support..  Blood.  94:368B-369B. 1999
  • Unrelated umbilical cord blood transplants in adult patients (pts) with hematologic malignancies or genetic disorders..  Blood.  94:570A-570A. 1999
  • The oncogenic E2A-HLF fusion protein protects leukemic B-precursor cells from apoptosis..  Blood.  86:1297-1297. 1995
  • SUCCESSFUL TREATMENT (RX) OF PATIENTS (PTS) WITH REFRACTORY SEVERE APLASTIC-ANEMIA (SAA) WITH CONCOMITANT CYCLOSPORINE (CSA) AND COLONY-STIMULATING FACTORS (CSF).  Blood.  84:A10-A10. 1994
  • A Role for the CRM1 Nuclear Export Receptor in HOXA Gene Deregulation and CALM-AF10Leukemogenesis.  Blood. 2017
  • Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data.  Blood. 2017
  • Beliefs and Patterns of Practice in the Management of Hyperleukocytosis and Leukostasis Among Health Care Providers for Patients with Acute Leukemia: A Large North American Web-Based Survey.  Blood. 2017
  • Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia.  Blood. 2017
  • Clinical Significance of PD-1 and PD-L1 Expression and Ongoing Interaction in the Tumor Microenvironment in Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP.  Blood. 2017
  • Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment.  Blood. 2017
  • Evaluation of Residual Disease Positivity Rates in Adult Acute Lymphoblastic Leukemia Patients Treated with Asparaginase Versus Non-Asparaginase Containing Regimens.  Blood. 2017
  • Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow.  Blood. 2017
  • Financial Burden and Patient-Reported Outcomes after Hematopoietic Cell Transplantation: Impact of Pre-Treatment Awareness of Transplant-Associated Costs.  Blood. 2017
  • IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia.  Blood. 2017
  • Insurance Design and Out-of-Pocket (OOP) Costs: a Comparison of Oral and Intravenous (IV) Treatment Plans for Chronic Lymphocytic Leukemia (CLL) in the Era of the Affordable Care Act (ACA).  Blood. 2017
  • Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study.  Blood. 2017
  • Multiple Myeloma Symptom Burden, Perceived Control, and Quality of Life: Findings from the Cancer Experience Registry.  Blood. 2017
  • PD-L1 Expression and Gene Amplification in CD30+Diffuse Large B-Cell Lymphoma (DLBCL): Significance of TP53 Genetic Impact and Clinicopathologic Characteristics.  Blood. 2017
  • Patient-Reported Distress in Hodgkin Lymphoma Patients on Active Therapy Vs. Long-Term Survivors.  Blood. 2017
  • Patient-Reported Sleep Quality at Baseline Correlates with 1-Year Survival after Allogeneic Hematopoietic Cell Transplantation in Adults.  Blood. 2017
  • Perceptions of Prognosis and Treatment Risk in Older Patients with Acute Myeloid Leukemia.  Blood. 2017
  • Pre-Transfusion Rejuvenation of RBCs for Red Blood Cell Exchange: Report of Feasibility.  Blood. 2017
  • Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study.  Blood. 2017
  • Quantification of Whole-Brain Oxygenation Extraction Fraction Among People with Sickle Cell Anemia without Stroke History.  Blood. 2017
  • Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib.  Blood. 2017
  • Results from the US Life after Stopping TKIs (LAST) Study.  Blood. 2017
  • Role of Glucose Transporter 1 in Graft-Versus-Host Disease and Graft-Versus-Tumor Effect.  Blood. 2017
  • The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation.  Blood. 2017
  • Transcript Expression, Intron Retention, and RNA Editing Are Conserved in Human Platelets over a 4 Year Period.  Blood. 2017
  • Transfusion Dependence and Use of Hospice Among Medicare Beneficiaries with Leukemia.  Blood. 2017
  • Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices.  Blood. 2017
  • Cell-Free DNA Is Elevated after Acute Arterial Injury in Infants.  Blood. 2016
  • Three Factor Prothrombin Complex Concentrates in Cardiac Surgery: A Novel Algorithmic Approach to Perioperative Bleeding.  Blood. 2016
  • A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition.  Blood. 2015
  • A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML).  Blood. 2015
  • A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies.  Blood. 2015
  • AAV Gene Therapy for MPS1 Corneal Clouding and Joint Stiffness.  Blood. 2015
  • Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.  Blood. 2015
  • Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study.  Blood. 2015
  • Autologous Cord Blood Infusion for the Treatment of Brain Injury in Children with Cerebral Palsy.  Blood. 2015
  • Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study.  Blood. 2015
  • Cord Blood Unit Cryopreservation: Positioning Segments for Potency Assessment.  Blood. 2015
  • Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial.  Blood. 2015
  • Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106.  Blood. 2015
  • Development of an Online Patient Decision Aid for Previously Treated Mantle Cell Lymphoma.  Blood. 2015
  • Dickkopf 1 (Dkk1) Regulates Hematopoietic Stem Cell Regeneration.  Blood. 2015
  • ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP).  Blood. 2015
  • Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi Institutional Review.  Blood. 2015
  • Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia.  Blood. 2015
  • Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches.  Blood. 2015
  • Genome-Wide Evaluation of Epistasis with APOL1 Risk Variants in Sickle Cell Disease Nephropathy.  Blood. 2015
  • Growth Factor Receptor-Bound Protein 10 (Grb10) Regulates Hematopoietic Stem Cell (HSC) Self-Renewal Via Control of mTOR Signaling.  Blood. 2015
  • Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone.  Blood. 2015
  • Impact of Available Therapies on Survival of Very Elderly Myelodysplastic Syndrome (MDS) Patients (Age above 75 yrs).  Blood. 2015
  • Impact of GvHD and Other Patient-, Disease-, Donor and Transplantation-Related Factors on 5 Year Relapse after Unrelated Cord Blood Transplantation for Children with Acute Lymphoblastic Leukemia in Remission.  Blood. 2015
  • Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML).  Blood. 2015
  • Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML).  Blood. 2015
  • Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants.  Blood. 2015
  • North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia.  Blood. 2015
  • Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit.  Blood. 2015
  • Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML).  Blood. 2015
  • Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials.  Blood. 2015
  • Prothrombin Complex Concentrates and Cardiac Surgery.  Blood. 2015
  • Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal.  Blood. 2015
  • Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306.  Blood. 2015
  • Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia.  Blood. 2015
  • SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML.  Blood. 2015
  • Symptom Burden, Quality of Life, and Distress in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy: Results of a Prospective Electronic Patient-Reported Outcomes Study.  Blood. 2015
  • TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia.  Blood. 2015
  • Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD).  Blood. 2015
  • The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status.  Blood. 2015
  • The Thrombotic Microangiopathy Registry of North America.  Blood. 2015
  • Thrombocytopenia in Hospitalized Non-ICU Patients.  Blood. 2015
  • beta-arrestin2 Is Necessary for Development of MPLW515L Mutant Primary Myelofibrosis.  Blood. 2015
  • A Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes with Prognosis.  Blood. 2014
  • A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.  Blood. 2014
  • Acute and Chronic Lymphocytic Leukemia Induces Exhaustion and Suppresses Metabolic Reprogramming in T Cell Activation.  Blood. 2014
  • Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program.  Blood. 2014
  • Atomic Level Description of the Immune Complex That Causes Heparin-Induced Thrombocytopenia (HIT).  Blood. 2014
  • Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization By Patients with Sickle Cell Disease.  Blood. 2014
  • Broncho-Alveolar Lavage and Lung Biopsy in Patients with Hematological Malignancy and Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review and Meta-Analysis.  Blood. 2014
  • Calcium Calmodulin Dependent Kinase Kinase 2 Regulates Hematopoietic Stem Cell Regeneration and Quiescence.  Blood. 2014
  • Clinical and Biological Features of Primary Testicular B-Cell Lymphoma - a Single-Institution Study of 89 Cases.  Blood. 2014
  • Clinician Approaches to Myeloma in Academia and the Community : An in-Practice Qualitative Study.  Blood. 2014
  • Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update.  Blood. 2014
  • Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.  Blood. 2014
  • Defining Immunoglobulin Somatic Hypermutation in De Novo Diffuse Large B-Cell Lymphoma Patients: Potential Application for Prognosis and Risk Stratification.  Blood. 2014
  • Double IGHV Gene Rearrangements in Chronic Lymphocytic Leukemia.  Blood. 2014
  • Effects of Sulforaphane Obtained from Broccoli Sprout Homogenate in Patients with Sickle Cell Disease (SCD).  Blood. 2014
  • Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG.  Blood. 2014
  • Epigenetics of Cellular Memory: Insights from the Chromatin Accessibility Landscape of the Mitotic Genome.  Blood. 2014
  • Evidence for a Dominant Negative Effect Conferred By the APOL1 G2 Sickle Cell Nephropathy Risk Allele in an in Vivo Model.  Blood. 2014
  • Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL).  Blood. 2014
  • Genes Associated with Alloimmunization to Blood Group Antigens in Sickle Cell Disease.  Blood. 2014
  • Genes Associated with Survival in Adult Sickle Cell Disease.  Blood. 2014
  • Genome-Wide Association Study of Glomerular Filtration Rate in a Cohort of Sickle Cell Disease Patients.  Blood. 2014
  • Growing Pains - Determination of Transfer and Transition from Pediatrics to Adult Outpatient Clinics for Patients with Sickle Cell Disease (SCD).  Blood. 2014
  • Growth Factor Receptor-Bound Protein 10 (Grb10) Regulates Hematopoietic Stem Cell Renewal.  Blood. 2014
  • Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR).  Blood. 2014
  • Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML).  Blood. 2014
  • Laboratory Assessment of Anti-Coagulant Properties of a Von Willebrand Factor Targeted Aptamer.  Blood. 2014
  • NF-kappa B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program.  Blood. 2014
  • Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL).  Blood. 2014
  • Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial.  Blood. 2014
  • Phase II study of (90)y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma.  Blood. 2014
  • Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience.  Blood. 2014
  • Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScope (TM)): Case Matched Analysis.  Blood. 2014
  • Protein Tyrosine Phosphatase-Sigma (PTP sigma) Regulates Hematopoietic Stem Cell Repopulating Capacity.  Blood. 2014
  • The CRM1 Nuclear Export Receptor Activates HOXA Gene Expression in Leukemogenesis.  Blood. 2014
  • Understanding the Underlying Immune Response in HIT: Uptake of PF4/Heparin Complexes By Monocytes & Dendritic Cells.  Blood. 2014
  • X-Ray Structure of an Anticoagulant RNA Aptamer Bound to Factor Xa. Structural Basis for Its Ability to Disrupt Interactions Between Xa and Va within Prothrombinase.  Blood. 2014
  • Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance).  Blood. 3903-3906. 2013
  • MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program.  Blood. 2013
  • NIH and National Foundation Expenditures For Sickle Cell Disease and Cystic Fibrosis Are Associated With Pubmed Publications and FDA Approvals.  Blood. 2013
  • STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report Fro The International DLBCL Rituximab-CHOP Consortium Program.  Blood. 2013
  • A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502.  Blood. 2012
  • Genetic Loss of Tmprss6 Increases Effective Erythropoiesis in a Mouse Model of beta-Thalassemia.  Blood. 2012
  • Modeling Variation in the Human Lymphoma Microenvironment with the E mu-Myc Mouse Model.  Blood. 2012
  • No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial.  Blood. 2012
  • Surgical Mask Usage Reduces the Incidence of Parainfluenza Virus 3 in Recipients of Stem Cell Transplantation.  Blood. 2012
  • Therapeutic Benefit of Small Molecule Inhibitors of MEK/ERK in Reducing Sickle Red Cell Adhesion and Vaso-Occlusion in Vivo.  Blood. 2012
  • A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia.  Blood. 724-724. 2011
  • A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes.  Blood. 231-232. 2011
  • A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response.  Blood. 666-667. 2011
  • ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet 'Favorable' Genetic Category.  Blood. 192-192. 2011
  • An Elevated Tricuspid Regurgitant Jet Velocity in Sickle Cell Disease Is Associated with Polymorphisms in Genes Impacting Innate Immunity.  Blood. 240-240. 2011
  • Biomarkers of Hemostatic Activation in a Randomized, Double-Blind, Phase 2 Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease.  Blood. 931-932. 2011
  • CALM Insufficiency Impairs Leukemia Cell Proliferation by Limiting Iron Uptake.  Blood. 642-642. 2011
  • CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report.  Blood. 116-116. 2011
  • Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma.  Blood. 1254-1255. 2011
  • Chemo-Mobilization Provides Superior Mobilization and Collection in Autologous Stem Cell Transplants but with Less Predictability and At a Higher Cost.  Blood. 1729-1729. 2011
  • Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells.  Blood. 132-133. 2011
  • Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol.  Blood. 226-227. 2011
  • Differences in Stem Cell Collection Practices and Related Outcomes Between Centers That Conduct and Do Not Conduct Aphaeresis on Weekends.  Blood. 839-840. 2011
  • Genomic Heterogeneity in B-Cell Malignancies.  Blood. 1480-1480. 2011
  • HIT Antibody Seropositivity and Thromboembolic Events After Cardiac Surgery.  Blood. 524-525. 2011
  • High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma.  Blood. 1152-1152. 2011
  • High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation.  Blood. 879-879. 2011
  • Hijacking the Niche: The Role of Stromal Osteopontin in the Induction of Leukemic Dormancy within the Bone Marrow Microenvironment.  Blood. 342-343. 2011
  • Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma.  Blood. 1765-1765. 2011
  • Inflammatory Polymorphisms Link the Risk of Acute Chest Syndrome with Asthma in Adults with Sickle Cell Disease.  Blood. 493-493. 2011
  • MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML).  Blood. 635-635. 2011
  • Personalizing Cancer Supportive Care: Predicting Neutropenic Complications in Patients Receiving Intermediate Risk Cancer Chemotherapy.  Blood. 469-469. 2011
  • Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures.  Blood. 1476-1477. 2011
  • Prevalence of MBL Increases Over Time In Relatives of CLL Families.  Blood. 1659-1659. 2011
  • Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG.  Blood. 1080-1080. 2011
  • Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts).  Blood. 190-191. 2011
  • Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia.  Blood. 778-779. 2011
  • Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia.  Blood. 1532-1533. 2011
  • Referral Patterns and Outcomes for Women with for Recurrent Pregnancy Loss Managed At a Multidisciplinary Thrombosis Program.  Blood. 1792-1793. 2011
  • Relationships Among Commonly Used Measures of Cord Blood Potency, ALDH(br) Cell Content, and Colony Forming Cell Content in Cord Blood Units Prior to Cryopreservation: Towards An Improved Metric for Potency of Banked Cord Blood.  Blood. 1731-1732. 2011
  • Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia.  Blood. 348-348. 2011
  • Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study.  Blood. 39-40. 2011
  • Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients.  Blood. 1125-1125. 2011
  • Sirolimus Inhibits Proliferation but Enhances Suppressive Activity of Rhesus Macaque Natural CD4 Regulatory T Cells.  Blood. 461-461. 2011
  • Tandem HLA-Mismatched Cadaveric Unrelated Donor Lung Transplant Followed by CD3-and CD19-Depleted Bone Marrow Transplant From the Same Donor Permits Withdrawal of Systemic Immunosuppression with Graft Acceptance and Functional Immune Reconstitution.  Blood. 460-461. 2011
  • The Impact of Factor IX Level on Thrombin Generation and Bleeding During Warfarin Anticoagulation.  Blood. 250-250. 2011
  • The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation.  Blood. 1736-1736. 2011
  • The Role of Surface Immunoglobulin Isotype in Chronic Lymphocytic Leukemia Disease Biology and Clinical Outcome.  Blood. 1229-1229. 2011
  • The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study.  Blood. 433-434. 2011
  • Transient Decrease in Factor VIII Following Delivery: Clearance or Consumption?.  Blood. 992-993. 2011
  • What Clinical Characteristics of Mothers and Babies Favorably Influence Cord Blood Potency? Defining Parameters That Can Guide Public Cord Blood Collection.  Blood. 225-226. 2011
  • Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma.  Blood. 199-200. 2011
  • Whole-Exome Sequencing Identifies Novel Risk Variant for Thrombotic Storm.  Blood. 552-552. 2011
  • A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study.  Blood. 1636-1636. 2010
  • A Comprehensive Comparison Immune Recovery In Adult Patients Following Allogeneic Umbilical Cord Blood, Matched Sibling and Matched Unrelated Donor Stem Cell Transplantation.  Blood. 954-955. 2010
  • A Novel Scoring System, the Cord Blood Apgar, Predicts Engraftment After Cord Blood Transplantation: Optimization of Selection of Cord Blood Units (CBUs) for Transplantation.  Blood. 158-158. 2010
  • A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies.  Blood. 1349-1350. 2010
  • A Randomized Trial of the Safety and Benefit of Transfusion Vs. Standard Care In the Prevention of Sickle Cell-Related Complications In Adults: a Preliminary Report From the Phase II NHLBI Comprehensive Sickle Cell Centers (CSCC) Study of Neuropsychological Dysfunction and Neuroimaging Abnormalities In Neurologically Intact Adult Patients with Sickle Cell Disease.  Blood. 1321-1321. 2010
  • A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML..  Blood. 883-884. 2010
  • ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.  Blood. 9-10. 2010
  • Allogeneic Effector Memory T Cells Enhance Hematopoietic Engraftment and Immune Reconstitution After Stem Cell Transplantation.  Blood. 41-41. 2010
  • Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma.  Blood. 351-352. 2010
  • An Ear-Tissue Model for High-Resolution In Vivo Imaging..  Blood. 623-623. 2010
  • Analysis of Risk Factors Influencing Outcomes After Unrelated Cord Blood Transplantation In Children with Juvenile Myelomonocytic Leukemia. An Eurocord, EBMT, EWOG-MDS, CIBMTR Study.  Blood. 237-238. 2010
  • Anti-Inflammatory Markers Are Associated with Glomerular Filtration Rate In Adults with Sickle Cell Disease.  Blood. 693-694. 2010
  • Atypical Activation of Plasma Membrane-Bound ERK1/2 Is Associated with Regulation of Sickle Red Cell Adhesion to Endothelium.  Blood. 122-122. 2010
  • Chronic Graft-Versus-Host Disease and Its Association with Treatment-Related Mortality, Relapse, Leukemia-Free and Overall Survival After Umbilical Cord Blood Transplantation (UCBT) In Children and Adolescents with Acute Leukemia.  Blood. 98-99. 2010
  • Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol.  Blood. 399-400. 2010
  • Dendritic Cell Activation by PF4/H Multimolecular Complexes.  Blood. 318-319. 2010
  • Disruption of PF4/Hep Multimolecular Complex Assembly Using a Minimally Anticoagulant Heparin (ODSH).  Blood. 319-319. 2010
  • Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a Comprehensive Review of Literature.  Blood. 1423-1424. 2010
  • Efficacy and Safety of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil (R)) plus G-CSF In Adult Patients with Non-Hematologic Malignancies..  Blood. 925-925. 2010
  • Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002.  Blood. 374-375. 2010
  • Efficacy of Denileukin Diftitox Retreatment In Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response.  Blood. 1179-1179. 2010
  • Facilitation of Hematopoietic Reconstitution Via Inhibition of Bone Marrow Endothelial Cell-Mediated SDF-1 Signaling.  Blood. 1578-1578. 2010
  • Factors Associated with Heterocellular Aggregate Formation In Sickle Cell Disease..  Blood. 1101-1101. 2010
  • GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease..  Blood. 685-686. 2010
  • Genetic Variation In MYH9 Is Associated with Sickle Cell Disease Nephropathy.  Blood. 692-692. 2010
  • Heparin Modifies the Immunogenicity of Positively-Charged Proteins.  Blood. 615-616. 2010
  • Hepcidin as a Therapeutic Tool to Limit Iron Overload and Improve Anemia In beta-Thalassemia.  Blood. 443-444. 2010
  • Hydroxyurea Reduces Conversion From Conditional to Abnormal TCD Velocities In Children with Sickle Cell Anemia (SCA).  Blood. 123-124. 2010
  • Identification of Thrombospondin-1 and L-Selectin as Potential Plasma Biomarkers of Silent Cerebral Infarct In Children with Sickle Cell Disease Using a Proteomic-Based Approach.  Blood. 119-119. 2010
  • Identification of a Costimulation Blockade Resistant Mechanism of Bone Marrow Allograft Rejection Induced by Infection with a Murine EBV Homologue..  Blood. 625-625. 2010
  • Increased Platelet Binding of NN1731, a Factor VIIa Variant with Enhanced Tissue Factor-Independent Activity.  Blood. 491-491. 2010
  • Initial Experience with the IMPROVE Trial-a Phase III Analgesic Trial for Hospitalized Sickle Cell Painful Episodes.  Blood. 1100-1100. 2010
  • Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci.  Blood. 1014-1014. 2010
  • Long-Term Follow-up of Adults with Severe Sickle Cell Disease After Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning.  Blood. 120-120. 2010
  • Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).  Blood. 1430-1431. 2010
  • Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study.  Blood. 48-49. 2010
  • Overall Survival of Lymphoma Patients In Randomized Controlled Trials Comparing Primary G-CSF Chemotherapy Support to Control.  Blood. 639-640. 2010
  • Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.  Blood. 1168-1169. 2010
  • Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS.  Blood. 1351-1351. 2010
  • Pleiotrophin Signaling Is Necessary and Sufficient for Hematopoietic Stem Cell Self-Renewal In Vivo.  Blood. 180-180. 2010
  • Post-Transplant Lymphoproliferative Disease In Liver Transplant Recipients: A Single Institution Experience.  Blood. 731-731. 2010
  • Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).  Blood. 768-769. 2010
  • Pregnancy In Type 1 Von Willebrand Disease: A Prospective Study of VWF Levels and Risk Factors for Bleeding..  Blood. 606-606. 2010
  • Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905.  Blood. 264-265. 2010
  • Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies..  Blood. 1456-1457. 2010
  • Reduced Intensity Conditioning In Children Undergoing Unrelated Umbilical Cord Blood Transplantation for Non-Malignant Diseases: Preliminary Results Demonstrate a High Rate of Engraftment and Low Incidence of Gvhd..  Blood. 1453-1454. 2010
  • Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation.  Blood. 104-105. 2010
  • Relationship of Soluble Adhesion Receptors to Red Cell Apoptosis In SCD.  Blood. 694-694. 2010
  • Resource Use and Expenditures Among Adult Sickle Cell Patients with and without Depression..  Blood. 653-653. 2010
  • S-Nitrosylation of Rap1and Relationship to Rap1 Activity and Disease Status In SCD.  Blood. 1098-1098. 2010
  • Six Year, Single Institution, off-Label Use of Recombinant Factor VIIa..  Blood. 603-603. 2010
  • Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas.  Blood. 1703-1704. 2010
  • The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship.  Blood. 1482-1482. 2010
  • The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study.  Blood. 288-288. 2010
  • The Serine Protease Tmprss6 Regulates Hepcidin Expression, but Its Loss Does Not Cause Systemic Iron Deficiency In the Fetal and Neonatal Periods.  Blood. 1728-1728. 2010
  • Tmprss6, An Inhibitor of Hepatic Bmp/Smad Signaling, Is Required for Hepcidin Suppression and Iron Loading In a Mouse Model of beta-Thalassemia.  Blood. 75-75. 2010
  • Transfusion Requirements and Outcomes In the Cohort of Patients Undergoing-Isolated CABG Treated with Prasugrel or Clopidogrel: TRITON-TIMI 38 Data Analysis.  Blood. 482-483. 2010
  • VE Cadherin Positive Endothelial Cells Regulate Hematopoietic Reconstitution In Vivo.  Blood. 1532-1532. 2010
  • Validation of the Cord Blood (CB) APGAR Score System to Predict Neutrophil Engraftment of Plasma Depleted CB Products.  Blood. 1459-1460. 2010
  • A Comprehensive Identification of the Microrna Transcriptome and Its Application in B Cell Malignancies.  Blood. 948-949. 2009
  • A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia.  Blood. 918-918. 2009
  • A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML..  Blood. 431-431. 2009
  • ALDH(br) Hematopoietic Progenitors Promote Short-Term Engraftment in Experimental Models for Cord Blood Transplantation..  Blood. 960-961. 2009
  • Acute Myeloid Leukemia or Myelodysplastic Syndromes and All-Cause Mortality in Randomized Controlled Trials of Cancer Patients Receiving Chemotherapy with or without Granulocyte Colony-Stimulating Factor: A Systematic Review and Meta-Analysis.  Blood. 1205-1205. 2009
  • Allospecific Effector Memory T Cells Are Able to Mediate Second-Set Skin Graft Rejection but Unable to Induce Graft-Versus-Host Disease.  Blood. 100-100. 2009
  • Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL..  Blood. 1332-1332. 2009
  • Characterization of Receptors Involved in Heparin Antibody Complex Mediated Induction of Tissue Factor Expression in Monocytes.  Blood. 97-98. 2009
  • Comparison of Thrombin Generation of Sickle Cell Patients in Microparticle Rich and Microparticle Poor Plasma Using Thrombin Generation Assay (TGA)..  Blood. 1004-1004. 2009
  • Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.  Blood. 814-814. 2009
  • Creation of a Segment-Based Aldehyde Dehydrogenase Assay as a Biomarker for Cord Blood Potency..  Blood. 1246-1247. 2009
  • Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.  Blood. 272-273. 2009
  • Deletion of Bak and Bax in Tie2+BM Hematopoietic Stem Cells Induces a B Cell Lymphoproliferative Disorder.  Blood. 513-513. 2009
  • Development of a Decision Support Tool to Guide Management of Adults with Sickle Cell Disease: The Emergency Department Sickle Cell Assessment of Strengths and Needs (ED-SCANS)..  Blood. 575-576. 2009
  • Effect of PAI-1 Specific RNA Aptamers On Cell Adhesion and Motility.  Blood. 840-840. 2009
  • Effects of Hydroxyurea (HU) and Magnesium Pidolate (Mg) in Hemoglobin SC Disease (HbSC): the "CHAMPS" Trial.  Blood. 338-338. 2009
  • Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.  Blood. 1272-1273. 2009
  • Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.  Blood. 511-511. 2009
  • Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia..  Blood. 73-74. 2009
  • Genome-Wide Studies in Sickle Cell Anemia Show Associations Between SNPs in the Olfactory Receptor Gene Cluster and Fetal Hemoglobin Concentration.  Blood. 339-339. 2009
  • Heparin Forms Macromolecular Complexes with Protamine and Lysozyme..  Blood. 538-539. 2009
  • Histone Deacetylase Inhibition Using LBH589 Is Effective in Lymphoma and Results in Down-Regulation of the NF-KB Pathway.  Blood. 1436-1437. 2009
  • Immunocompromised Status of Patients with Hematologic and Solid Tumor Malignancies: Construction of a Practical Algorithm.  Blood. 980-980. 2009
  • Impact of Nucleated Cell Dose On Engraftment and Survival After Unrelated Cord Blood Transplantation for Severe Aplastic Anemia: A Retrospective Study On Behalf of Eurocord and the EBMT SAA WP.  Blood. 1240-1241. 2009
  • Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.  Blood. 866-867. 2009
  • In-Hospital Outcomes Among Sickle Cell Patients with Acute Chest Syndrome: Results From a National Database..  Blood. 557-557. 2009
  • Increased Severity of Pandemic H1N1 Influenza in Children and Young Adults with Sickle Cell Disease.  Blood. 112-112. 2009
  • Influence of Statin Therapy On the Clinical Course of Chronic Lymphocytic Leukemia.  Blood. 926-926. 2009
  • Long-Term Survival and Late Deaths After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism.  Blood. 1287-1288. 2009
  • Loss of Function of the VHL Tumor Suppressor Gene Resurrects An Endogenous Retrovirus in Kidney Cancer That Encodes a Tumor Antigen Targeted by Allogeneic T-Cells Following Hematopoietic Cell Transplantation (HCT).  Blood. 193-193. 2009
  • Low Levels of Apolipoprotein A1 Are Associated with Silent Cerebral Infarets in Children with Sickle Cell Disease.  Blood. 109-110. 2009
  • Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission..  Blood. 425-426. 2009
  • Molecular Profiling Identifies Plasmablasts as the Cells of Origin of Activated Diffuse Large B Cell Lymphoma.  Blood. 257-257. 2009
  • Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).  Blood. 1277-1277. 2009
  • Overexpression and Phosphorylation of eIF4E Is Required for Beta-Catenin Activation in Blast Crisis Chronic Myelogenous Leukemia.  Blood. 22-22. 2009
  • Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study..  Blood. 457-458. 2009
  • Physiologic Hypoxia Protects Chronic Myelogenous Leukemia Progenitors From Elimination by Imatinib Mesylate.  Blood. 858-858. 2009
  • Plerixafor (Mozobil (R)) Selectively Enhances Donor Hematopoietic Cell Engraftment.  Blood. 155-155. 2009
  • Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL)..  Blood. 669-669. 2009
  • Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.  Blood. 326-327. 2009
  • Prevention of Acute GvHD During MHC Haploidentical BMT: Evaluating the Efficacy of T-Cell Costimulation Blockade Using a Novel Rhesus Macaque Transplant Model..  Blood. 968-969. 2009
  • Proteomic-Based Approach for Biomarker Discovery to Predict Silent Cerebral Infarct in Patients with Sickle Cell Disease.  Blood. 1012-1013. 2009
  • Racial Differences in Thrombotic Risk Factors Associated with Adverse Pregnancy Outcome Among Women Obtaining Care in US Thrombosis and Hemostasis Centers.  Blood. 1164-1164. 2009
  • Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.  Blood. 325-326. 2009
  • Retrospective Review of the Natural History of Pulmonary Hypertension in Sickle Cell Disease Demonstrates That Progressive Enlargement of the Left Atrium Is a Strong Predictor of Death..  Blood. 613-614. 2009
  • Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.  Blood. 822-823. 2009
  • The Anti-Inflammatory Investigational Agent LMP-420 Demonstrates in Vitro Cytotoxic Activity against Chronic Lymphocytic Leukemia Cells.  Blood. 931-931. 2009
  • The Complex Relationship Between Sickle Cell Disease and Depression.  Blood. 1014-1015. 2009
  • Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.  Blood. 367-368. 2009
  • Thymic Recovery and De Novo T Cell Production During the First Year After Unrelated Cord Blood Transplant (UCBT) Predicts Overall Survival: A Multivariate Analysis of 93 Patients Following Myeloablative Conditioning and a Single Unit Graft..  Blood. 481-482. 2009
  • Tie2+Bone Marrow Endothelial Cells Regulate Hematopoietic Reconstitution In Vivo.  Blood. 106-106. 2009
  • Tmprss6 Is a Genetic Modifier of the Hfe-Hemochromatosis Phenotype in Mice.  Blood. 259-259. 2009
  • Transplantation Following Myeloablative Cytoreduction Results in Excellent Survival, Long-Term Engraftment, and Donor Chimerism in Children with Chronic Granulomatous Disease Across Donor and Graft Sources.  Blood. 1319-1319. 2009
  • Use of Aldehyde Dehydrogenase Content to Predict Dominating Cord in Double Cord Blood Transplant.  Blood. 847-848. 2009
  • Use of a Computer Based Neurocognitive Software Program in Asymptomatic Neurologically Intact Adults with Sickle Cell Disease..  Blood. 612-612. 2009
  • Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study.  Blood. 181-181. 2008
  • Comprehensive Ultra High Resolution Analysis of Copy Number and Allele Status Including Novel Microdeletions Spanning NF1 in Acute Myelogenous Leukemia.  Blood. 1066-1066. 2008
  • Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.  Blood. 800-800. 2008
  • Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial..  Blood. 369-370. 2008
  • Final Risk Prediction Model for Neutropenic Complications in Patients Receiving Cancer Chemotherapy.  Blood. 474-475. 2008
  • Identification of p53 Aberration-Dependent as Well as Non-p53-Mediated Resistance to MDM2 Inhibitors in Acute Myelogenous Leukemia.  Blood. 569-569. 2008
  • Insulin-Like Growth Factor 1 Protects against Lethal Irradiation..  Blood. 1196-1196. 2008
  • Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.  Blood. 749-749. 2008
  • Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy.  Blood. 209-209. 2008
  • Prevention of Acute GvHD during Haplo-BMT: Evaluating the Efficacy of T-Cell Costimulation Blockade Using a Novel Rhesus Macaque Transplant Model.  Blood. 1207-1207. 2008
  • Single Donor 4/6 Matched Banked Unrelated Cord Blood Is An Effective Graft Source for Children Undergoing Myeloablative Transplantation for Malignant and Nonmalignant Disorders: Single Center Analysis of 318 Patients.  Blood. 690-690. 2008
  • Standard Versus Dose-Intensified Chemotherapy with Granulocyte Colony-Stimulating Factor for Malignant Lymphoma: Evaluation of Risk for Acute Myeloid Leukemia or Myelodysplastic Syndrome.  Blood. 833-833. 2008
  • Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome: Results of a Randomized Comparative Phase III Study.  Blood. 340-341. 2008
  • A conditional risk model for chemotherapy-induced anemia (CIA) in cancer patients..  Blood. 117A-117A. 2007
  • Avoidance of post-thaw wash prior to transplantation of plasma depleted cord blood (PD CB) is associated with improved engraftment & decreased severity of chronic GvHD (cGvHD) without increased relapse.  Blood. 494A-494A. 2007
  • Blocking adhesion of sickle erythrocytes to endothelial P-selectin using an RNAaptamer.  Blood. 51A-51A. 2007
  • Clinical and outcomes findings for thrombotic thrombocytopenic purpura among 467 persons with severely versus not severely deficient ADAMTS13 levels.  Blood. 622A-622A. 2007
  • Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.  Blood. 73A-73A. 2007
  • Further investigation of the role of factor XIII in priapism associated with SCD.  Blood. 998A-998A. 2007
  • Genomic complexity identifies patients with agressive chronic lymphocytic leukemia..  Blood. 151A-151A. 2007
  • Inhibition of nitric oxide synthase (NOS) 1, NOS2, and NOS3 enzymatic activities by vitamin B-12 and related corrins: Biochemical and molecular modeling studies.  Blood. 783A-783A. 2007
  • Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14 with differential expression of LATS2.  Blood. 617A-617A. 2007
  • Sickle RBCs stimulate human monocyte cytokine expression.  Blood. 668A-669A. 2007
  • Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-incluced mobilization.  Blood. 72A-72A. 2007
  • The relationship of opiate analgesia to quality of life in an adult sickle cell population.  Blood. 670A-670A. 2007
  • Changes in the pattern of cytogenetic aberrations with advancing age in acute myeloid (Non-APL) leukemia: A Southwest Oncology study (S9007)..  Blood. 242A-242A. 2006
  • Coagulopathy from severe postpartum hemorrhage..  Blood. 116B-116B. 2006
  • Current prevalence of specific clinical outcomes in adult patients with HbSS or Hb S beta(0) thalassemia..  Blood. 353A-353A. 2006
  • Defects in E2F1/2 expression are associated with abnormalities in cell cycle and differentiation in EKLF-deficient erythroid cells..  Blood. 29A-29A. 2006
  • Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post SCT: Final results of a multi-center, randomized, dose-finding trial..  Blood. 17A-18A. 2006
  • Determinants of PF4/heparin immunogenicity in a murine model of HIT..  Blood. 32A-33A. 2006
  • Effect of single dose in vivo propranolol therapy on in vitro adhesion of human SS RBC..  Blood. 363A-363A. 2006
  • Impaired maturation and survival of T lymphocytes, B lymphocytes, and NK cells in mice lacking Gimap5/Ian5..  Blood. 276A-276A. 2006
  • Interaction of activated sickle red cell LW with leukocytes induces leukocyte adhesion to endothelium via CD44-E-selectin..  Blood. 361A-361A. 2006
  • MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease (MPD), and in Philadelphia-positive ALL..  Blood. 556A-557A. 2006
  • Mechanism of soluble laminin-mediated enhancement of sickle red cell adhesion to endothelial cells..  Blood. 364A-364A. 2006
  • Preliminary results from the surveillance, epidemiology & risk factors for TTP (SERF-TTP) group: A prospective case-control study of idiopathic TTP..  Blood. 316A-317A. 2006
  • Prospective validation of a predictive model for early anemia in patients receiving cancer chemotherapy..  Blood. 140A-140A. 2006
  • Restoring initial thrombin generation does not normalize cutaneous wound healingin hemophilia B..  Blood. 306A-306A. 2006
  • Role of erythropoietin as an angiogenic factor and target in cancer..  Blood. 127A-127A. 2006
  • Unrelated donor hematopoietic stem cell transplantation (HSCT) in children with acute leukemia: Risks and benefits of umbilical cord blood (CB) versus HLAA, B, C, DRB1 allele-matched bone marrow (BM)..  Blood. 133A-133A. 2006
  • A differentiation block in erythroid cells lacking erythroid krupple-like factor (EKLF)..  Blood. 157A-157A. 2005
  • A phase 2 clinical trial of AP23573, an mTOR inhibitor, In patients with relapsed or refractory hematologic malignancies.  Blood. 835A-836A. 2005
  • A prospective study of bortezomib in combination with melphalan and prednisone for patients with previously untreated multiple myeloma..  Blood. 379B-379B. 2005
  • A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition..  Blood. 121A-121A. 2005
  • A report of the event free survival (EFS) for children with newly diagnosed standard risk acute lymphoblastic leukemia (ALL) treated on pediatric oncology group (POG) protocol 9605..  Blood. 257A-257A. 2005
  • A report of the event-free survival (EFS) and neurotoxicity for children with newly diagnosed standard risk acute lymphoblastic leukemia (ALL) on pediatric oncology group (POG) protocol 9405..  Blood. 259A-259A. 2005
  • A single cell analysis of immunoglobulin genes in chronic lymphocytic leukemia (CLL): Evidence of intraclonal diversification associated with progressive somatic mutations and progressive antigen drive in immunoglobulin heavy and light chains.  Blood. 346A-347A. 2005
  • ADAMTS13 levels support hypothesis of distinct mechanistic pathways for early versus late-onset of thienopyridine-associated thrombotic thrombocytopenic purpura (TTP)..  Blood. 22A-22A. 2005
  • Adhesive characteristics of hemoglobin SC red blood cells..  Blood. 23B-24B. 2005
  • Antigen-specific T lymphocyte function following unrelated cord blood transplantation (UCBT)..  Blood. 849A-849A. 2005
  • CD26 inhibition enhances allogeneic donor cell homing and engraftment after in utero bone marrow transplantation..  Blood. 371A-371A. 2005
  • Clinical and genetic profiles of the aging sickle cell patient..  Blood. 26A-26A. 2005
  • Defibrotide (DF) for the treatment of Veno-Occlusive Disease (VOD) and multi-system organ failure (MOF) post SCT: Analysis of response and survival according to degree and type of MOV..  Blood. 120A-120A. 2005
  • Delayed wound healing in hemophilia B mice..  Blood. 894A-894A. 2005
  • Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia (ALL) - Cancer and leukemia group B study 9511.  Blood. 519A-519A. 2005
  • Erythropoietin and erythropoietin receptor expression in early stage non-small cell lung cancer: Prognostic significance..  Blood. 145B-145B. 2005
  • Ex vivo expansion of umbilical cord blood T cells for adoptive immunotherapy..  Blood. 15A-15A. 2005
  • Gene expression patterns identify novel biologically relevant signaling and transcriptional pathways involved in terminal erythroid differentiation and polycythemia vera.  Blood. 984A-984A. 2005
  • Incident TTP: Plasmapheresis therapy-related complications are common..  Blood. 365A-365A. 2005
  • Induction of chronic lymphocytic leukemia (CLL) apoptosis by nitric oxide synthase (NOS) inhibitors: Drug efficacy correlates with lipid solubility and NOS1 dissociation constant..  Blood. 342B-343B. 2005
  • Left sided heart dysfunction in sickle cell disease: Echocardiographic and genetic studies..  Blood. 27A-27A. 2005
  • Morbidity and associated sudden death in sickle cell disease..  Blood. 661A-661A. 2005
  • Multimodal dose dense therapy for mantle cell lymphoma..  Blood. 463B-463B. 2005
  • Partially HLA matched, non-myeloablative allogeneic transplantation.  Blood. 812A-812A. 2005
  • Pathogenic role of surface platelet factor 4 complexes in heparin-induced thrombocytopenia: Diagnostic and therapeutic implications..  Blood. 21A-21A. 2005
  • Predictors of survival in CLL: Multivariate analyses reveal significant correlation with IgV(H) gene mutation status, clinical stage, and cellular CD38 (but not Zap-70) expression..  Blood. 334B-334B. 2005
  • Priapism in SCD: Clinical and genetic correlations..  Blood. 887A-887A. 2005
  • Rapid in vivo acquisition of effector Tc1 phenotype even before myeloid engraftment predicts opportunistic infections (OI) in unrelated cord blood transplant recipients..  Blood. 409A-409A. 2005
  • Reaction of fibrinogen with homocysteine thiolactone mimics the dysfibrinogenemia produced by hyperhomocysteinemia..  Blood. 44A-44A. 2005
  • Role of LW and AKAP79 in beta-adrenergic receptor signaling-induced sickle red blood cell adhesion..  Blood. 889A-889A. 2005
  • Sodium orthovanadate (NaV) effects CD22 expression, intracellular signaling, and lymphomacidal activity of the HB22.7 anti-CD22 monoclonal antibody..  Blood. 428A-428A. 2005
  • The relationship of plasma laminin levels to anemia and the effect of soluble laminin on sickle red cell adhesion in SCD..  Blood. 657A-657A. 2005
  • Thrombotic and hemorrhagic events for patients on pediatric oncology group (POG) protocols 9201, 9605, 9406..  Blood. 258A-259A. 2005
  • Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin..  Blood. 164A-164A. 2005
  • CALGB 59901: Results of a phase II study of 506U78 in CTCL and PTCL..  Blood. 682A-682A. 2004
  • Characterization of autoantibodies to PF4/heparin in a rat model of cardiopulmonary bypass..  Blood. 825A-825A. 2004
  • Cord blood (CB) bank log CD34(+) and CD34(+) subsets (CD38(-)CD61(+)CD90(+)) are significantly correlated to log total CFU, CFU-GEMM, CFU-GM and BFU-E: A report from the COBLT program.  Blood. 119A-119A. 2004
  • Dose dense, high intensity therapy in newly diagnosed elderly patients with acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg (TM)) and high dose cytarabine (HiDAC)..  Blood. 212B-213B. 2004
  • Ex vivo gene therapy of a preadolescent with x-linked severe combined immunodeficiency.  Blood. 120A-120A. 2004
  • FLT3 signaling is not necessary to the leukemogenic properties of MLL fusion genes in a marine model..  Blood. 706A-706A. 2004
  • Gemtuzumab ozogamicin (Mylotarg (R)) as primary induction therapy for elderly patients with acute myeloid leukemia: A phase II trial.  Blood. 210B-210B. 2004
  • Heparin-induced thrombocytopenia is a thymus (T cell) dependent disorder..  Blood. 825A-825A. 2004
  • Human memory T cells proliferate but do not elicit cytotoxicity in response to alloantigens..  Blood. 347A-347A. 2004
  • Pharmacogenetics of minimal residual disease response in children with acute lymphoblastic leukemia (ALL)..  Blood. 132A-132A. 2004
  • Promotion of stem cell-derived new T cell generation by CD62L-memory T cells requires alloantigen recognition..  Blood. 831A-831A. 2004
  • Recryopreserved and rethawed aliquots with anti-CD3, IL-2, IL12 significantly expands NKT cells, NKT KIR substes and NK cytotoxicity compared to short-term expansion: Potential for CB adoptive cellular immunotherapy (ACI)..  Blood. 778A-778A. 2004
  • The association of an early hemoglobin response with alternative metrics to evaluate treatment efficacy of erythropoietic agents..  Blood. 71A-71A. 2004
  • The use of DT388-IL3 fusion protein in patients with refractory acute myeloid leukemia(AML).  Blood. 212B-212B. 2004
  • A cost-effectiveness evaluation of imatinib versus interferon-alpha plus low-dose Ara-C for first-line treatment of patients with newly diagnosed chronic myeloid leukemia in the chronic phase..  Blood. 252A-252A. 2003
  • A novel method for ex-vivo expansion of NKCD3-/CD16+/56(+bright/dim) subjects expressing increased inhibitory receptors from cryopreserved/thawed/expanded/recryopreserved (CTECT) umbilical cord blood (UCB) using anti-CD3, IL-2, IL-7, and IL-12 (AB/CY): Implications for adoptive cellular immunotherapy (ACI) post umbilical cord blood transplantation (UCBT).  Blood. 963A-964A. 2003
  • A single cell analysis of immunoglobulin genes in chronic lymphocytic leukemia (CLL): Progressive somatic mutations in the immunoglobulin heavy and light chains contribute to intraclonal diversification in CLL..  Blood. 666A-666A. 2003
  • Activity of compound 506U78 in patients with refractory T-cell malignancies: A POG/CCG intergroup phase 2 study..  Blood. 226A-226A. 2003
  • B-CAM/LU polymorphisms: Effect on sickle cell disease outcomes and cell adhesion..  Blood. 28B-28B. 2003
  • Bronchiolitis obliterans organizing pneumonia (BOOP) after bone marrow transplantation (BMT) for sickle cell disease (SCD): Association with acute chest syndrome (ACS)..  Blood. 460B-461B. 2003
  • Characterization of neuronal/glial differentiation of murine adipose-derived adult stromal cells..  Blood. 180B-180B. 2003
  • Chronic lymphocytic leukemia cells (CLL) express the neuronal isoform of nitric oxide synthase (NOS1), and NOS1-specific inhibitors induce CLL cell death..  Blood. 353B-353B. 2003
  • Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy from HLA matched siblings..  Blood. 238A-239A. 2003
  • Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy using HLA mis-matched (3-5/6) related hematopoietic stem cells..  Blood. 482A-482A. 2003
  • Clopidogrel-associated TTP: Comparison of quality and timeliness of case reports obtained from the FDA, the pharmaceutical supplier, and from active pharmacovigilance..  Blood. 496A-497A. 2003
  • Clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): Clinical characteristics and predictors of survival..  Blood. 539A-539A. 2003
  • Combined infusion of peripheral blood stem cells (PBSC) plus bone marrow (BM) in poorly mobilizing patients undergoing high-dose therapy (HDT) and autologous stem cell transplant (ASCT).  Blood. 988A-989A. 2003
  • Complement-mediated hemolysis of erythrocytes is blocked by RNA aptamers to complement components C5 and C8..  Blood. 510A-510A. 2003
  • Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Results of a phase II, multicenter, randomized study..  Blood. 193A-193A. 2003
  • Dose-intense cyclophosphamide and etoposide for patients with refractory or high risk non-Hogdkin's lymphoma..  Blood. 287B-287B. 2003
  • Ex vivo expansion of umbilical cord blood (UCB) derived immature and mature T cells..  Blood. 965A-965A. 2003
  • Examination of a VCAM1 polymorphism as a risk modifier for clinical outcomes in sickle cell disease..  Blood. 29B-29B. 2003
  • Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation..  Blood. 396B-396B. 2003
  • In vitro exposure to epinephrine causes in vivo adhesion of human sickle red blood cells to vascular endothelium in nude mice: A new model for studying vaso-occlusion..  Blood. 261A-261A. 2003
  • Incidence, characteristics, and treatment of DVT in pregnant and postpartum women from the DVT FREE registry..  Blood. 808A-808A. 2003
  • Isolation of oligodendrocyte precursors from umbilical cord blood..  Blood. 965A-966A. 2003
  • Low-dose weekly paclitaxel for relapsed or refractory aggressive non-Hodgkins lymphoma..  Blood. 641A-641A. 2003
  • One day preparative regimen for allogeneic non-myeloablative stem cell transplantation (NMSCT) using 3-5/6 HLA matched related donors..  Blood. 476B-477B. 2003
  • Outcomes of 138 adult and pediatric patients undergoing cord blood transplantation from large cord blood bank..  Blood. 479A-479A. 2003
  • Pharmacokinetics of subcutaneous alemtuzumab in a patient with myeloma..  Blood. 385B-385B. 2003
  • Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma..  Blood. 635A-636A. 2003
  • Phase one evaluation of gemcitabine, fludarabine, and mitoxantrone for relapsed or refractory leukemia..  Blood. 250B-250B. 2003
  • Platelet transmission electron microscopy in genetically confirmed MYH9-related disorders..  Blood. 788A-789A. 2003
  • Platelets stimulated with convulxin plus thrombin develop platelet subpopulations with increased binding of factor VIII, factor IX, and factor X..  Blood. 293A-293A. 2003
  • Preliminary results of unrelated umbilical cord blood transplantation for Sanfilippo syndrome (MPS III)..  Blood. 481A-481A. 2003
  • Protein phosphatase inhibitors as potent cytotoxic agents for B-cell CLL in vitro..  Blood. 360B-360B. 2003
  • Results of the cord blood transplantation study (COBLT) unrelated donor banking program from donor screening to characterization of banked units..  Blood. 461A-461A. 2003
  • Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation..  Blood. 871A-871A. 2003
  • Sickle RBCs form microaggregates in autologous plasma following epinephrine stimulation: A role for endogenous, soluble laminin..  Blood. 82A-82A. 2003
  • Splenectomy prior to umbilical cord blood (UCB) transplantation facilitates hematologic engraftment in pediatric and adult patients..  Blood. 470A-471A. 2003
  • Successful treatment of pure red cell aplasia (PRCA) with alemtuzumab (CAMPATH-1H)..  Blood. 19B-19B. 2003
  • TEPA augments the ex-vivo and in-vivo potential of cord blood derived CD34+cells: From basic science to clinical trials..  Blood. 961A-961A. 2003
  • The interaction of platelets and endothelial cells modulates the procoagulant/anticoagulant balance in heparin-induced thrombocytopenia..  Blood. 805A-805A. 2003
  • The small GTPase rapl activates BCAM/LU-dependent but not alpha 4 beta l-dependent adhesion in sickle red blood cells: Evidence for divergent adhesive pathways..  Blood. 82A-82A. 2003
  • Thrombocytopenia is common among patients treated with heparin and is rarely detected and evaluated with serologic testing and hematology consultation: Preliminary findings from the CATCH registry..  Blood. 537A-537A. 2003
  • Umbilical cord blood cells engraft and differentiate in cardiac tissues after human transplantation..  Blood. 153B-153B. 2003
  • Unrelated donor umbilical cord blood transplantation for X-linked adrenoleukodystrophy..  Blood. 479B-479B. 2003
  • cAMP-dependent activation of sickle red blood cell adhesion is associated with LW serine and tyrosine phosphorylation..  Blood. 263A-263A. 2003
  • Ability of minority patients to find donors from an ethnically diverse cord blood bank..  Blood. 640A-641A. 2002
  • Anti-CD3/IL-2/IL-7/IL-12 ex-vivo expansion of previously cryopreserved and subsequent recryopreservation of umbilical cord blood (UCB) cytotoxic T lymphocytes: A new procedure for adoptive cellular immunotherapy (ACI) post UCB transplant (T)..  Blood. 58A-58A. 2002
  • B-CAM/LU mediates laminin-independent cell-cell adhesion under both static and flow conditions..  Blood. 451A-451A. 2002
  • Campath-1H, T cell depleted nonmyeloablative peripheral blood stem cell transplantation from 3-6/6 HLA matched family members..  Blood. 638A-638A. 2002
  • Chronic lymphocytic leukemia (CLL) cell CD38 expression and inducible nitric oxide synthase (NOS2) expression are associated with serum IL-4 levels..  Blood. 357B-357B. 2002
  • Clinical evaluation of retroviral vectors for corrective gene transfer of adenosine deaminase (ADA) deficiency..  Blood. 116A-116A. 2002
  • Correction of congenital immunodeficiency disease with umbilical cord blood transplantation..  Blood. 858A-858A. 2002
  • Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT)..  Blood. 112A-112A. 2002
  • Donor chimerism after T-Cell depleted (TCD)-Non-Myeloablative allogeneic SCT (NST) in hemoglobinopathies..  Blood. 401B-402B. 2002
  • Donor-specific tolerance after hematopoietic reconstitution with Campath-1H treated mobilized peripheral blood cells in a sublethal preconditioning regimen..  Blood. 410A-410A. 2002
  • Early T cell reconstitution along with graft and patient characteristics impact on opportunistic infections following unrelated cord blood transplantation in children..  Blood. 841A-841A. 2002
  • Elevated expression of numerous interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis..  Blood. 584A-584A. 2002
  • Ex vivo expansion of CB derived AC 133 progenitor cells with a polyamine copper chelator: Pre-clinical data..  Blood. 419B-419B. 2002
  • Ex vivo propagation and expansion of umbilical cord blood derived immature and mature T-cells..  Blood. 833A-833A. 2002
  • Failure of a minimally toxic non-myeloablative regimen to establish stable donor engraftment after transplantation for sickle cell anemia and beta-thalassemia..  Blood. 46A-46A. 2002
  • Fatal rapidly progressive liver disease associated to a novel mutation of the perforin gene..  Blood. 466A-466A. 2002
  • Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin..  Blood. 339A-339A. 2002
  • Gene expression profiling of AAV serotype 1-5 vectors in adult and neonatal animals using in vivo bioluminescence imaging..  Blood. 220A-220A. 2002
  • Immunological and clinical responses in patients with metastatic renal cell carcinoma to vaccination with tumor RNA transfected dendritic cells..  Blood. 867A-867A. 2002
  • Immunophenotypic and functional characterization of CD4+ CD25+ regulatory T cells as a function of aging in normal human peripheral blood and autoimmune disease..  Blood. 250A-250A. 2002
  • In vitro priming and generation of cytomegalovirus-specific T cell responses from umbilical cord blood..  Blood. 54B-55B. 2002
  • In vivo engraftment and differentiation of murine adipose derived stromal cells..  Blood. 731A-731A. 2002
  • Intracellular inositol polyphosphatides signaling via factor VIIa and factor X: The possible role of protease-activated receptor 2 and tissue factor activation..  Blood. 69B-69B. 2002
  • Modulation by epinephrine of PKA-dependent signaling pathways in sickle red blood cells induces activation of LW binding to endothelial cell alpha v beta 3 integrin..  Blood. 118A-118A. 2002
  • Morpholino antisense oligomer to integrin alpha, inhibits angiogenesis in a mouse model of retinopathy of prematurity..  Blood. 680A-680A. 2002
  • Nucleated cell count and CD34+count similar between cord blood units collected from Caucasian and non Caucasian umbilical cord blood donors..  Blood. 618A-618A. 2002
  • Philadelphia-chromosome (Ph+) acute lymphoblastic leukemia (ALL) in children and adolescents: Outcome with unrelated placental cord blood (PCB) transplantation..  Blood. 856A-856A. 2002
  • Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome..  Blood. 795A-795A. 2002
  • Racial/ethnic diversity achieved in national network of cord blood banks..  Blood. 186A-186A. 2002
  • Relationship of sickle red blood cell laminin binding to disease activity..  Blood. 450A-451A. 2002
  • Successful treatment of lymphoma xenografts with the anti-CD22 mAb HB22.7 alone and augmented response when given with Y90-DOTA-PEPTIDE-LYM-1 that is sequence specific..  Blood. 315B-315B. 2002
  • Three methods of T-cell depletion of HPCT products: Analysis of CD34+ cell and lymphocyte purity and recovery..  Blood. 835A-836A. 2002
  • Treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT): 2 year follow-up..  Blood. 864A-864A. 2002
  • Treatment of severe systemic sclerosis with allogenic marrow transplantation..  Blood. 460B-461B. 2002
  • Unrelated umbilical cord blood (UCB) transplantation for infants with acute lymphoblastic leukemia (ALL) and rearrangements of the 11q23 chromosomal region..  Blood. 855A-856A. 2002
  • Unrelated umbilical cord blood transplant for Wiskott-Aldrich syndrome..  Blood. 855A-855A. 2002
  • Updated results of bone marrow transplantation (BMT) for sickle cell disease (SCD): Impact on CNS disease..  Blood. 45A-46A. 2002
  • Within-trial resource utilization and costs of patients randomized to treatment with imatinib (STI571) versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in newly diagnosed patients with chronic myeloid leukemia in chronic phase..  Blood. 187A-187A. 2002
  • Effect of hyperhomocysteinemia on protein C activation and activity in vivo..  Blood. 257A-258A. 2001
  • Enumerating functionally mature monocyte-derived dendritic cells for use in cancer immunotherapy..  Blood. 851A-851A. 2001
  • High dose factor VIIa enhances clot stability in a model of hemophilia..  Blood. 826A-827A. 2001
  • Quantitating antigen specific T cell responses in peripheral blood: A comparison of peptide MHC tetramer, ELISpot and intracellular cytokine analysis..  Blood. 23A-23A. 2001
  • Addition of stem cells from allogeneic donors accelerates engraftment and immune reconstitution after stem cell transplantation..  Blood. 172A-172A. 2000
  • Dendritic cell (DC) reconstitution after non-myeloablative allogeneic stem cell transplants..  Blood. 305B-305B. 2000
  • Hematopoiteic stem cell doses correlate with the speed of immune reconstitution after allogeneic stem cell transplantation..  Blood. 772A-772A. 2000
  • Hyperhomocysteinemia induces alterations in fibrinogen function and fibrin clot structure in a rabbit model..  Blood. 39A-39A. 2000
  • Hyperhomocysteinemia induces monocyte tissue factor (TF) expression in vivo..  Blood. 32B-32B. 2000
  • Multiple signals are required for IL-12 production by Flt-3 ligand mobilized dendritic cells..  Blood. 295A-295A. 2000
  • Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) followed by hematopoietic stem cell transplantation..  Blood. 320A-320A. 2000
  • V beta repertoire of T lymphocytes emerging in adults after unrelated umbilical cord blood (UCB) allogeneic transplantation..  Blood. 788A-788A. 2000
  • Activated protein C (APC) functions by inhibiting initiation of coagulation rather than by terminating a hemostatic response..  Blood. 224A-224A. 1999
  • De-encryption of cellular tissue factor is independent of its cytoplasmic domain..  Blood. 227A-227A. 1999
  • Efficacy and safety of CMA-676 in patients with AML in first relapse..  Blood. 696A-696A. 1999
  • FLT3-ligand (FLT3L) mobilization of dendritic cells (DC) in patients with metastatic colon cancer..  Blood. 48A-48A. 1999
  • Impaired immune function in murine adult cord blood recipients..  Blood. 568A-568A. 1999
  • Reconstitution of the immunohematopoietic system in adult murine recipients across major histocompatibility complex by near-term fetal blood..  Blood. 321A-321A. 1999
  • Residual trisomic cells in a patient with resolving transient myeloproliferative disorder and trisomy 21 mosaicism..  Blood. 291B-291B. 1999
  • The initial rate, but not the total amount, of thrombin (IIa) generated determines fibrin clot structure in a cell-based model of coagulation..  Blood. 230A-231A. 1999
  • Tissue factor independent effect of high dose factor VIIa directly correlates with factor X levels..  Blood. 228A-228A. 1999